Second Biotherapeutic Partnership of 2021 SAN CARLOS, Calif., April 26, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with a leading Japanese biotechnology company related to BioCardia Helix catheter biotherapeutic delivery product candidates. Under the terms of the agreement, BioCardia will receive $500,000, […]
Coronary/Structural Heart
Experience with BioTrace Medical’s Tempo Temporary Pacing Lead in Mitral Valve Surgeries Presented at Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting
Case series demonstrates the advantages of transvenous active-fixation Tempo Lead over epicardial leads for minimally invasive cardiac surgery procedures MENLO PARK, Calif.–(BUSINESS WIRE)–BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company’s Tempo® Temporary Pacing Lead was featured in a patient case series presented at the […]
NICE Renews Support for Use of AI-powered HeartFlow Analysis in Heart Disease Diagnosis
The National Institute for Health and Care Excellence (NICE) finds HeartFlow Analysis can save NHS England as much as £391 per patient The digital technology is reducing reliance on unnecessary invasive diagnostic procedures and is cutting hospital waiting times The announcement follows NHS England’s MedTech Funding mandate, which went into effect on 01 […]
Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2
VAZKEPA (icosapent ethyl) is the first and only authorized treatment for its cardiovascular risk reduction indication1,2,3 VAZKEPA authorization for Great Britain follows recent VAZKEPA authorization for European Union DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2021 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) today announced that the Medicines and […]
Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. The BIOADAPTOR […]
Medtronic Receives U.S. FDA Approval for Pipeline™ Flex Embolization Device with Shield Technology™
First Patient Receives New Shield Surface Modification, An Advance in Flow Diversion Therapy, at NYU Langone Health DUBLIN, April 21, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for Pipeline™ Flex Embolization Device […]
Vesalius Cardiovascular Reaches a New and Advanced Pre-Clinical Milestone
In a first-of-its-kind study, Vesalius proves that its catheter-based anchoring to the papillary muscle is safe and durable VANCOUVER, BC, April 21, 2021 /PRNewswire/ — Vesalius Cardiovascular Inc. (VCI), a Canadian MedTech company developing a Transfemoral Mitral Valve Repair (TMVr) solution, announced today the achievement of a new pre-clinical milestone with its 180-day […]
Quantum Genomics Will Present Top-line Results From its QUORUM Study of Firibastat in Heart Failure Post Myocardial Infarction at the European Society of Cardiology (ESC) Meeting
PARIS, April 21, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, will present top-line results from its QUORUM study of firibastat in heart […]
Prevencio Announces Laboratory Commercialization Partnership with Atlas Genomics Incorporating Microsoft’s AI-computing Cloud
Commercial Launch Follows Successful Beta Testing of Prevencio’s Highly Accurate AI-driven HART Tests KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc. today announces an Agreement with Atlas Genomics to commercially launch its highly accurate, AI-driven HART blood tests for heart disease and risk of heart attack, stroke, and cardiovascular death. The HART blood tests are […]
BioStable Science & Engineering Announces CE Mark Approval for the HAART 200 Aortic Annuloplasty Device & Surpasses 1,000 Patients Treated Worldwide with the HAART Devices
AUSTIN, Texas–(BUSINESS WIRE)–BioStable Science & Engineering, Inc. (“BioStable”) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair. With CE Mark approval of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable will be able to […]
